Table 3.
Estimates from linear regression predicting 1-yr post-KT eGFR among recipients of LDKTs
| Variable | Unadjusted (Model 1L), β (95% CI) | Recipient Characteristics (Model 2L), β (95% CI) | Donor and Organ Characteristics (Model 3L), β (95% CI) | Immunosuppression Practice (Model 4L), β (95% CI) | Post-Transplant Course (Model 5L), β (95% CI) | Fully Adjusted (Model 6L), β (95% CI) |
|---|---|---|---|---|---|---|
| Transplant period (2011–2013 versus 2001–2005) | 0.66 (0.32 to 1.01) | 1.03 (0.68 to 1.39) | 1.82 (1.49 to 2.16) | −0.46 (−0.84 to −0.08) | 0.43 (0.09 to 0.77) | 0.67 (0.31 to 1.04) |
| Recipient characteristics | ||||||
| Age (per 10 yr) | ||||||
| Age ≤40 | −2.71 (−3.13 to −2.29) | −2.24 (−2.64 to −1.85) | ||||
| 40<age≤55 | −0.52 (−0.91 to −0.14) | 0.12 (−0.23 to 0.48) | ||||
| Age >55 | 0.60 (0.18 to 1.01) | 1.02 (0.63 to 1.41) | ||||
| Race (ref=White) | ||||||
| Black | 4.93 (4.45 to 5.40) | 4.76 (3.87 to 5.65) | ||||
| Hispanic | 4.61 (3.89 to 5.34) | 3.02 (2.23 to 3.81) | ||||
| Other | 6.22 (5.73 to 6.72) | 3.86 (2.87 to 4.84) | ||||
| Male (ref=female) | 0.89 (0.55 to 1.22) | 1.17 (0.85 to 1.49) | ||||
| Peak PRA (ref=0) | ||||||
| Missing PRA | −0.35 (−1.14 to 0.45) | −0.64 (−1.41 to 0.12) | ||||
| 0<peak PRA≤20 | −0.21 (−0.61 to 0.19) | −0.14 (−0.52 to 0.23) | ||||
| 20<peak PRA≤80 | −0.13 (−0.66 to 0.40) | −0.15 (−0.65 to 0.35) | ||||
| Peak PRA ≥80 | −0.38 (−1.29 to 0.52) | −0.35 (−1.21 to 0.50) | ||||
| Length of pretransplant dialysis (per yr) | 0.12 (0.04 to 0.20) | 0.14 (0.07 to 0.21) | ||||
| With diabetes yes (ref=no) | 1.73 (1.36 to 2.11) | 1.65 (1.30 to 2.01) | ||||
| Recipient weight (ref=normal: 18.5≤BMI<25) | ||||||
| Recipient BMI missing | −2.05 (−2.64 to −1.45) | −2.13 (−2.69 to −1.57) | ||||
| Underweight (18.5<BMI) | 3.64 (2.58 to 4.71) | 3.72 (2.73 to 4.72) | ||||
| Overweight (25≤BMI<30) | −2.39 (−2.80 to −1.97) | −2.42 (−2.80 to −2.03) | ||||
| Obese (BMI≥30) | −4.11 (−4.55 to −3.67) | −4.10 (−4.51 to −3.69) | ||||
| Donor and organ factors | ||||||
| Age (per 10 yr) | ||||||
| Age ≤25 | −1.83 (−3.73 to 0.06) | −1.12 (−2.96 to 0.71) | ||||
| Age >25 | −4.10 (−4.26 to −3.94) | −3.98 (−4.13 to −3.82) | ||||
| Male (ref=Female) | 3.48 (3.16 to 3.80) | 3.53 (3.22 to 3.84) | ||||
| Race (ref=White) | ||||||
| Black | 2.26 (1.78 to 2.74) | −1.73 (−2.66 to −0.80) | ||||
| Hispanic | 4.21 (3.73 to 4.69) | 1.25 (0.46 to 2.04) | ||||
| Other | 3.38 (2.63 to 4.12) | −0.51 (−1.56 to 0.54) | ||||
| Number of HLA mismatch (A, B, DR) | −0.29 (−0.38 to −0.19) | −0.13 (−0.22 to −0.04) | ||||
| Donors with hypertension | −0.83 (−2.16 to 0.51) | −0.49 (−1.78 to 0.80) | ||||
| Immunosuppression practice | ||||||
| Induction (ref=anti-IL2R) | ||||||
| Polyclonals | −1.33 (−1.74 to −0.92) | −0.76 (−1.15 to −0.38) | ||||
| Alemtuzumab | −0.54 (−1.18 to 0.11) | −0.55 (−1.15 to 0.05) | ||||
| No induction recorded | −0.16 (−0.60 to 0.28) | −0.14 (−0.54 to 0.26) | ||||
| Choice of CNI for maintenance (ref=cyclosporine) | ||||||
| Tacrolimus | 4.33 (3.89 to 4.77) | 3.99 (3.59 to 4.40) | ||||
| No CNI recorded | 3.67 (2.85 to 4.50) | 4.37 (3.61 to 5.13) | ||||
| Choice of antiproliferative for maintenance (ref=mTOR inhibitora) | ||||||
| Mycophenolate | 2.74 (2.17 to 3.30) | 2.84 (2.32 to 3.36) | ||||
| Azathioprine | 3.50 (1.92 to 5.07) | 4.03 (2.58 to 5.48) | ||||
| Other agents or none | 1.77 (0.89 to 2.65) | 1.48 (0.67 to 2.29) | ||||
| Post-transplant course | ||||||
| DGF | −4.76 (−5.71 to −3.80) | −4.53 (−5.42 to −3.63) | ||||
| Acute rejection by 1 yr | −8.98 (−9.49 to −8.46) | −8.24 (−8.72 to −7.76) |
These models included 38,822 recipients with no missing variables. 95% CI, 95% confidence interval; ref, reference group; PRA, panel-reactive antibodies; CNI, calcineurin inhibitor.
a
mTOR inhibitor group included those on both mTOR inhibitor and mycophenolate.